Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EXAS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEXASExact Sciences$48.01+1.2%$48.79$38.81▼$72.83$8.98B1.053.87 million shs2.32 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEXASExact Sciences+1.24%+4.12%+0.52%-12.98%-22.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEXASExact Sciences4.8099 of 5 stars4.53.00.04.73.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEXASExact Sciences 2.91Moderate Buy$67.0539.66% UpsideCurrent Analyst Ratings BreakdownLatest EXAS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/12/2025EXASExact SciencesBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$65.00 ➝ $60.008/11/2025EXASExact SciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$70.00 ➝ $60.008/8/2025EXASExact SciencesEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$68.00 ➝ $64.008/7/2025EXASExact SciencesCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy8/7/2025EXASExact SciencesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$61.00 ➝ $53.008/7/2025EXASExact SciencesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$54.00 ➝ $46.008/7/2025EXASExact SciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$65.00 ➝ $55.007/8/2025EXASExact SciencesEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$66.00 ➝ $68.006/24/2025EXASExact SciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$75.00 ➝ $65.00(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEXASExact Sciences$2.76B3.29$5.70 per share8.42$13.04 per share3.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEXASExact Sciences-$1.03B-$5.43N/A96.024.85-34.19%-1.75%-0.76%11/4/2025 (Estimated)Latest EXAS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025EXASExact Sciences-$0.02$0.22+$0.24-$0.01$774.43 million$811.09 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEXASExact SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEXASExact Sciences0.942.892.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEXASExact Sciences88.82%Insider OwnershipCompanyInsider OwnershipEXASExact Sciences1.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEXASExact Sciences7,000189.32 million187.05 millionOptionableEXAS HeadlinesRecent News About These CompaniesLansforsakringar Fondforvaltning AB publ Decreases Stake in Exact Sciences Corporation $EXAS4 hours ago | marketbeat.comIeq Capital LLC Buys 18,292 Shares of Exact Sciences Corporation $EXAS4 hours ago | marketbeat.comHow Record Q2 Results and a New US$150 Million Savings Plan at Exact Sciences (EXAS) Have Changed Its Investment StorySeptember 2 at 3:38 PM | finance.yahoo.comExact Sciences Corporation $EXAS Stock Holdings Lifted by Armistice Capital LLCSeptember 2 at 8:12 AM | marketbeat.comJefferies Reiterates a Buy Rating on Exact Sciences Corporation (EXAS)August 31 at 8:40 AM | finance.yahoo.comExact Sciences Corporation $EXAS Shares Acquired by Rafferty Asset Management LLCAugust 30, 2025 | marketbeat.comNorthern Trust Corp Decreases Stock Position in Exact Sciences Corporation $EXASAugust 30, 2025 | marketbeat.comChamplain Investment Partners LLC Cuts Stock Position in Exact Sciences Corporation $EXASAugust 29, 2025 | marketbeat.comAlphaQuest LLC Raises Stock Holdings in Exact Sciences Corporation $EXASAugust 29, 2025 | marketbeat.comThematics Asset Management Decreases Holdings in Exact Sciences Corporation $EXASAugust 27, 2025 | marketbeat.comBRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Boosts Holdings in Exact Sciences Corporation $EXASAugust 26, 2025 | marketbeat.comExact Sciences Corporation $EXAS Position Cut by Ameriprise Financial Inc.August 26, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Purchases 643,631 Shares of Exact Sciences Corporation $EXASAugust 26, 2025 | marketbeat.comBI Asset Management Fondsmaeglerselskab A S Has $502,000 Stake in Exact Sciences Corporation $EXASAugust 26, 2025 | marketbeat.comExact Sciences Corporation $EXAS Position Boosted by Hsbc Holdings PLCAugust 26, 2025 | marketbeat.comKorea Investment CORP Has $4.93 Million Stock Holdings in Exact Sciences Corporation $EXASAugust 25, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Sells 1,350,794 Shares of Exact Sciences Corporation $EXASAugust 24, 2025 | marketbeat.comAnalysts Set Exact Sciences Corporation (NASDAQ:EXAS) Target Price at $67.43August 24, 2025 | americanbankingnews.comCandriam S.C.A. Lowers Stock Holdings in Exact Sciences Corporation $EXASAugust 23, 2025 | marketbeat.comState of New Jersey Common Pension Fund D Reduces Stock Holdings in Exact Sciences Corporation $EXASAugust 23, 2025 | marketbeat.comExact Sciences Corporation $EXAS Shares Bought by Aberdeen Group plcAugust 23, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEXAS Company DescriptionsExact Sciences NASDAQ:EXAS$48.01 +0.59 (+1.24%) Closing price 09/2/2025 04:00 PM EasternExtended Trading$48.00 -0.01 (-0.02%) As of 08:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Tests $412 Support as Options Traders Turn Bullish Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Kohl’s Stock Rebound Faces a Showdown With Short Sellers Amazon Faces Rare Downgrade—Is the Rally at Risk? What to Watch for From D-Wave Now That Earnings Are Done Alibaba Rallies on New AI Chip Design, Sending NVIDIA Stock Lower 3 High-Yield Stocks Just Supercharged Their Dividends Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
